Enliven Therapeutics, Inc. Profile Avatar - Palmy Investing

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being …

Biotechnology
US, Boulder [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Enliven Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Enliven Therapeutics, Inc. can't present revenue by segment

End of ELVN's Analysis
CIK: 1672619 CUSIP: 29337E102 ISIN: US29337E1029 LEI: - UEI: -
Secondary Listings
ELVN has no secondary listings inside our databases.